Prophylactic Antibiotic Treatment During Vaginal Repair

Prolapse of the uterus, bladder and rectum is a common condition in multiparous and/or elderly women. The number of operations for vaginal repair is increasing in Denmark, but there is no consensus or evidence found about the efficiency of prophylactic antibiotics intraoperatively concerning postoperative infections. The objective of this randomized, controlled trial is to investigate the...

Date First Received: September 9, 2005

Last Updated: September 8, 2006

Verified by: Hvidovre University Hospital, February 2005

Clinical Trial Phase: N/A | Start Date: May 2005

Overall Status: Recruiting

Estimated Enrollment: 200

Brief Summary

Official Title: “Antibiotikaprofylakse Ved Vaginalplastik”

Intervention(s):

Prolapse of the uterus, bladder and rectum is a common condition in multiparous and/or elderly women. The number of operations for vaginal repair is increasing in Denmark, but there is no consensus or evidence found about the efficiency of prophylactic antibiotics intraoperatively concerning postoperative infections.

The objective of this randomized, controlled trial is to investigate the significance of prophylactic antibiotic treatment in vaginal repair operations.

Study Type: Interventional

Study Design: Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment

Intervention(s) in this Clinical Trial

  • Drug: Cefuroxime

Outcome Measures for this Clinical Trial

Primary Measures

  • primary endpoint: no infections (urinary tract infections, pneumonia,wound infections, infected haematomas, etc.) within 30 days postoperatively

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • Women ages 18+ with uterine prolapse grade I - II and/or cystocele and/or rectocele and/or enterocele grade I - II and/or defects of the perineal body, in whom there is medical indication for vaginal repair, but no indication for vaginal hysterectomy or transvaginal suspension of the vaginal vault after prior hysterectomy.

Exclusion Criteria:

  • Patients allergic to cefuroxime.
  • Patients in whom a vaginal hysterectomy or a transvaginal suspension of the vaginal vault or other major surgery is planned, where prophylactic antibiotic treatment is standard.
  • Patients suffering from physical or mental disorders that will not allow them to give informed consent.
  • Pregnant and nursing women.

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: Hvidovre University Hospital

Overall Clinical Trial Officials and Contacts

Marianne Ottesen, M.D, Ph.D Study Director Hvidovre University Hospital  

Overall Contact: Marianne Ottesen, M.D 0045 36323632 marianne.8sen@dadlnet.dk

Additional Information

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00162604

Study ID Number: 2602-415

ClinicalTrials.gov Identifier: NCT00162604

Health Authority: Denmark: Danish Medicines Agency

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.